Clinical Trial Update: Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating neoadjuvant PD-1 antibody alone or with dendritic cell vaccines for recurrent glioblastoma is in progress with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Dendritic Cell Vaccines
• PD-1 antibody (PD-1 inhibitor)

Snippet

Sponsor: Huashan Hospital | Conditions: Recurrent Glioblastoma | Phase 2 | Status: UNKNOWN